Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data

Acrivon Therapeutics shares plunged 28.71% to $2.1044 after the company released updated Phase 2b data for ACR-368 in endometrial cancer; interim results showed a 52% confirmed response rate in serous-subtype patients with two or fewer prior lines of therapy and a 67% rate in biomarker-positive subjects. The company said it will expand the trial into the EU to accelerate enrollment, but investors interpreted the mixed clinical readout negatively, driving unusually high intraday volatility and volume (intraday range roughly $1.98–$3.12; 52-week range ~$1.05–$8.00).

Analysis

Contrarian Angles: Consensus discounts ACRV due to headline volatility but may be missing the high ORR in biomarker-positive serous patients — if confirmatory DOR >9 months and biomarker sensitivity/specificity >70% within 6–9 months, upside could be 3x+ from current levels. The market reaction looks overdone given small cohort early readouts, but dilution risk from faster EU roll-out is underpriced. Historical parallels: small-cap oncology names with strong biomarker-driven signals (e.g., early ADC/targeted therapy names) have swung 3–5x on confirmatory data, implying asymmetric payoff for limited, option-defined exposure. Unintended consequence: aggressive enrollment expansion could accelerate cash burn and force a financing at <$3, which would materially reduce current equity value.

Key Decisions for Investors

• Establish a tactical, size-limited long in ACRV equal to 1–2% of portfolio via shares between $1.80–$2.50 with a stop-loss at $1.20 (≈40% downside from entry) and take-profit target at $5.00 within 9–12 months conditional on positive DOR/PFS signals or validated biomarker metrics.
• If options liquidity permits, buy a 9–12 month ACRV call spread: buy the $2.50 call and sell the $5.00 call to cap cost; allocate position size equal to 0.5–1% of portfolio to limit downside while retaining upside to a positive readout.
• Construct a pair trade for sector-neutral exposure: long ACRV (0.5–1% of NAV) and short XBI or IBB equal delta notional to hedge sector volatility for a 3–6 month trade while awaiting more detailed subgroup/DOR data.
• Reduce exposure to undifferentiated small-cap clinical biotech by 2–5% of portfolio and reallocate to large-cap, cash-flowing biopharma (e.g., PFE, MRK) until micro-cap IV normalizes; reassess after company publishes DOR and biomarker performance within 60–120 days.
• Monitor three hard triggers over the next 60–120 days before increasing exposure: (1) median DOR or 6-month DOR rate >50% in biomarker-positive cohort, (2) published biomarker sensitivity/specificity ≥70%, and (3) cash runway extending >12 months without a financing announcement; act only if ≥2 triggers are met.